skip to primary navigationskip to content

Cancer Research UK - Immunology call

last modified Oct 22, 2016 01:13 PM
At Cancer Research UK we recognise that immunology has underpinned some of the most exciting discoveries in modern cancer research. We are committed to supporting cutting-edge immunology to deepen our understanding of the interactions between the immune system and tumours.

Our Cancer Immunology Project Awards aim to attract established immunologists working in fields other than cancer, to bring their expertise and insight to cancer research.
The scheme has a broad remit. Research could include outreaching biology covering the whole immunological process, from inflammation, to the innate and adaptive immune responses. There's a spectrum of expertise that fits into what we're looking for. Previous funded projects include: 

• A study of the immunotherapeutic potential of MHC class I restricted peptiede activation of human natural killer cells, led by Salim Khakoo, professor of hepatology at the University of Southampton.
• A project investigating the novel hypothesis that the complement system promoted inflammation driven cancer, but not others, combining the complementary expertise of Marina Botto (rheumatology) and Jessica Strid (skin epithelial cell biology).

The awards provide funding of up to £300,000 over three years and the next deadline is 8 November 2016. There are two deadlines throughout the year - you can read more about eligibility for the scheme on our website

Immunologists who already have a demonstrated track record in cancer research can also apply for our Programme Awards.

We also offer the opportunity to translate great immunology research with our Therapeutic Discovery Awards - Biotherapeutic Drug Discovery Awards and Small Molecule Drug Discovery Awards. These awards fund translational research projects at all stages of drug discovery, from target and pathway identification and validation, through to early preclinical studies. Awards can support early stage translational research with a clear pathway towards further therapeutic development (i.e. cell-, antibody-, gene-, protein-, vaccine- and viral-based or small molecule therapies). There are two deadlines a year for project awards, which provide funding of up to £100,000 per annum for up to 3 years. For our Biotherapeutic Drug Discovery Awards there is one deadline a year and for programme awards, which provide funding £2.5 million per annum for up to 5 years. Successful applicants to our Biotherapeutic Drug Discovery Awards will also have the opportunity to access the CRUK-MedImmune Alliance Laboratory (CMAL). CMAL provides access to MedImmune’s proprietary phage display library, and can support antibody production. Applicants wishing to access the CMAL should include this in their application.

The next deadline for preliminary submissions of project and programme applications is Mid November 2016.

The new Capella building- CITIID

See the home of CITIID being built in this fantastic time-lapse video. From basement to water tight in 17 months. The Capella building will be finished in 2019.


‘Fibroblast’ has been developed from a conversation between Harold Offeh and Dr Alice Denton, a scientist based at the Babraham Institute and a member of the Cambridge Immunology Network. Offeh was particularly interested in the character and roles played by particular cells in the immune system, as well as the immune system’s role as a primary source of protection and care. The film takes as a starting point microscopic images of broblast cells, an area of research for Dr Denton.

FCEs provide interdisciplinary training programmes for students, fellows and continuing education physicians through FOCIS assisted opportunities

Read more